Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Skye Bioscience, Inc. related to misrepresentation of the company's product effectiveness and prospects [1][2]. Group 1: Legal Investigation - Kuehn Law is looking into whether Skye Bioscience's insiders misrepresented the effectiveness of nimacimab, leading to overstated clinical, regulatory, and commercial prospects [2]. - The investigation is prompted by a federal securities lawsuit alleging that public statements made by Skye Bioscience were materially false and misleading [2]. Group 2: Shareholder Participation - Shareholders who purchased SKYE shares prior to November 4, 2024, are encouraged to contact Kuehn Law to enforce their rights, as there may be limited time to act [3]. - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of shareholder involvement in maintaining market integrity [4].